Genfleet Therapeutics (2595 HK)

Analysis

Health Care • China

Genfleet Therapeutics is a biopharmaceutical company focused on developing innovative treatments for oncology, including various solid tumors, and autoimmune and inflammatory diseases. The company's pipeline includes products like GFH925 (fulzerasib) for advanced non-small cell lung cancer and GFH375, a KRAS G12C inhibitor. Genfleet Therapeutics was incorporated in 2017 and is headquartered in Shanghai, China.

Refresh

Exchange Announcement • 13 Oct 2026 18:58

Next Day Disclosure Return

Exchange Announcement • 08 Oct 2026 19:42

Next Day Disclosure Return

Exchange Announcement • 28 Sep 2026 17:51

Next Day Disclosure Return

Exchange Announcement • 24 Sep 2026 16:37

List Of Directors And Their Roles And Functions

Exchange Announcement • 24 Sep 2026 16:31

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Next Day Disclosure Return

Next Day Disclosure Return

Next Day Disclosure Return

List Of Directors And Their Roles And Functions

Resignation Of Non-Executive Director